Alex Herrera on Nivolumab/Brentuximab Vedotin Combination for Patients with Hodgkin Lymphoma

Alex Herrera discusses the response of patients with Hodgkin lymphoma on combination nivolumab/brentuximab vedotin.

Alex Herrera, MD, City of Hope Cancer Center, discusses patients’ reaction in the phase I/II trial of combination nivolumab/brentuximab vedotin in the second-line for patients with Hodgkin lymphoma.

Herrera emphasizes monitoring for infusion-related reactions when treating patients taking these two drugs together. There was an increased rate of these reactions in the study. However, the infusion-related reactions seen were mostly mild and were able to be treated with the standard supportive therapies. After treatment, the patients were able to resume infusion as normal.